Intranasal Epinephrine (Neffy)
Canadian Journal of Health Technologies · 20.11.2026 · 6 (11)
DOI: 10.51731/cjht.2026.1573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 20.11.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Intranasal epinephrine, 2 mg, nasal spray, intranasal administration. Indication: Emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis in adult and pediatric patients who weigh 30 kg or greater.
Zitieren
APA
CDA-AMC (2026). Intranasal Epinephrine (Neffy). Canadian Journal of Health Technologies, 6(11). https://doi.org/10.51731/cjht.2026.1573
Vancouver
CDA-AMC. Intranasal Epinephrine (Neffy). Canadian Journal of Health Technologies. 2026;6(11). doi:10.51731/cjht.2026.1573
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Intranasal Epinephrine (Neffy)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {11},
doi = {10.51731/cjht.2026.1573}
}
EUVIMED